Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

(2014) Jun-ichi Kira et al.   BMC Neurology

Regulation of IL-17 in Human CCR6+ Effector Memory T Cells

(2014) H. Liu et al.   JOURNAL OF IMMUNOLOGY

Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis

(2014) Douglas Kazutoshi Sato et al.   JOURNAL OF NEUROIMMUNOLOGY

Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis

(2013) Takuya Matsushita et al.   PLoS One

Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status

(2012) Satoshi Yoshimura et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

(2012) T Saida et al.   Multiple Sclerosis Journal

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod

(2012) Sebastian Jander et al.   Multiple Sclerosis Journal

Tumefactive multiple sclerosis lesions under fingolimod treatment

(2012) F. Visser et al.   NEUROLOGY

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

(2011) Ju-Hong Min et al.   Multiple Sclerosis Journal

The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

(2011) B. Soliven et al.   NEUROLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Regulation of human Th9 differentiation by type I interferons and IL-21

(2010) Michael T Wong et al.   IMMUNOLOGY AND CELL BIOLOGY

Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis

(2010) Kenji Chiba et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

(2010) M. Mehling et al.   NEUROLOGY

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β

(2009) Luca Durelli et al.   ANNALS OF NEUROLOGY

IL-9 as a mediator of Th17-driven inflammatory disease

(2009) Elizabeth C. Nowak et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes

(2009) A. Jager et al.   JOURNAL OF IMMUNOLOGY

Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese

(2009) T Matsushita et al.   Multiple Sclerosis Journal

Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis

(2008) M. Tanaka et al.   NEUROLOGY

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

(2008) M. Mehling et al.   NEUROLOGY